Bisphosphonates for the prevention and treatment of osteoporosis

P and T

Volumn 27, Issue 10, 2002, Pages 506-513

  Boothby, Lisa Anne ^a,b,c  

^a AUBURN UNIVERSITY   (United States)

^b The Medical Center   (United States)

^c MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; COLECALCIFEROL; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CORTICOSTEROID; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ARTHRALGIA; BREAST CANCER; CALCIUM INTAKE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; META ANALYSIS; NAUSEA; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT COUNSELING; REVIEW; RISK ASSESSMENT; RISK FACTOR; THORAX PAIN; TREATMENT OUTCOME; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 0036821197     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Walker-Bone K, Walter G, Cooper C. Recent developments in the epidemiology of osteoporosis. Curr Opin Rheumatol 2002;14(4):411-415.
2. Melton LJ III. Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 2000;15:2309-2314.
3. Cummings SR, Black DM, Rubin SM. Lifetime risk of hip, Colles', or vertebral fracture and coronary heart disease among white post-menopausal women. Arch Intern Med 1989;149(11):2445-2448.
4. Cummings SR, Melton LJ III. Epidemiology and outcomes of osteoporosis fracture. Lancet 2002;359:1761-1767.
5. Osteoporosis among estrogen deficient women: U.S., 1988-1994. MMWR Morb Mortal Wkly Rep 1998;47(45):969-973.
6. Osteoporosis Task Force. American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract 2001;7(4):293-312.
7. National Institutes of Health (NIH) Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 2001;285(6):785-795.
8. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344(5):333-340.
9. Saag KG, Emkey R, Schnitzer TJ, et al. Aledronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339(5):293-299.
10. Dawson-Huges B, Harris SS, Krall EA, Dalal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337(10):670-676.
11. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanove G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339(14):947-952.
12. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Eng J Med 1996;334(8):488-493.
13. Whittington R, Faulds D. Hormone replacement therapy: II. A pharmacoeconomics appraisal of its role in the prevention of post-menopausal osteoporosis and ischemic heart disease. Pharmacoeconomics 1994;5(6):513-554.
14. Geelhoed E, Harris A, Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health 1994;18(2):153-160.
15. Rosner AJ, Grima DT, Torrance GW, et al. Cost-effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Pharmacoeconomics 1998;14(5):559-573.
16. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy post- menopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288(3):1-26.
17. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274(2):137-142.
18. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332(24):1589-1593.
19. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288(1):49-57.
20. Effects of hormone replacement therapy on bone mineral density: Results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. The Writing Group for the PEPI trial. JAMA 1996;276(17):1389-1396.
21. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288(1):58-66.
22. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345(17):1243-1249.
23. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343(8):522-529.
24. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275(5):370-375.
25. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 2000;109(4):267-276.
26. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 2002;162:1140-1143.
27. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999;281(23):2189-2197.
28. Iglesias CP, Torgerson DJ, Bearne A, Bose U. The cost utility of bisphosphonates treatment in established osteoporosis. QJM 2002;95(5):305-311.
29. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of aledronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-1541.
30. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis. N Engl J Med 1995;333(22):1437-1443.
31. Drug Facts and Comparisons, 55th ed. St. Louis: Facts and Comparisons®;2001:286-293.
32. th ed. Montvale, NJ: Medical Economics Company; 2002:2099,2882-2883.
33. Cremers, Sparidans R, Hartigh JD, Hamdy N, Vermeij P, Papapoulos S. A pharmacokinetic and pharmacokdynamic model for bisphosphonates (pamidronate) in osteoporosis. Eur J Clin Pharmacol 2002;57:883-890.
34. AHFS Drug Information 2002. ASHP, Bethesda, MD: 2002; 3704-3706;3575-3578.
35. Reid IR, Burckhardt P, Horowitz Z, A et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346(9):653-661.
36. Horiuchi T, Onouchi T, Inove J, Shionoiri A, Hosoi T, Orimol T. A strategy for the management of elderly women with primary hyperparathyroidism: A comparison of etidronate therapy with parathyroidectomy. Gerontology 2002;48(2):103-108.
37. Mercadante S. The use of bisphosphonates in the management of bone metastatic prostate cancer. Curr Urol Rep 2002;3(3):244-249.
38. Macedo J, Macedo C, Elkis H, DeOliveira I. Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis. J Clin Pharmacol Ther 1998;23(5):345-353.
39. Cranney A, Welch V, Adachi JD, et al. Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev 2001;(4):CD003376.
40. Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000;(2):CD001347.
41. Drake WM, Kendler DL, Brown JP. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance Symposium. Clin Ther 2001;23(4):620-626.
42. Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate: A meta-analysis. JAMA 1997;278(8):631-632.
43. Taggart H, Bolognese MA, Lindsay R, et al. Upper gastrointestinal tract safety of risedronate: A pooled analysis of 9 clinical trials. Mayo Clin Proe 2002;77(3):262-270.
44. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86(5):1890-1897.
45. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87(3):985-992.
46. Palombra S, Orio F, Colao A, et al. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87(4):1502-1508.
47. Cortet B, Bera-Louville A, Gauthier P, Gauthier A, Marchandise X, Delcambre B. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis: Effect of adding hormone replacement therapy. Joint Bone Spine 2001;68(5):410-415.
48. Dursin N, Dursun E, Talcin S. Comparison of alendronate, calcitonin, and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 2001;55(8):505-509.
49. Tonino Rp, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: Seven-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 2000;85(9):3109-3115.
50. Levis S, Quandt SA, Thompson D, et al. Aledronate reduces the risk of multiple symptomatic fractures: Results from the Fracture Intervention Trial. JAm Geriatr Soc 2002;50(3):409-415.
51. Bell NH, Bilezikian JP, Bone HG, Kaur A, Maragoto A, Santora AC. Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab 2002;87(6):2792-2797.
52. Greenspan SL, Schneider DL, McClung MR, et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long term care facilities: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;742-746.
53. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial JAMA 1998;280(24):2077-2082.
54. Hosking D, Chilvers ED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338(8):485-492.
55. Harris ST, Watts NB, Genant HK, et al. Effect of risedronate treatment on nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 1999;282(14):1344-1352.
56. Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporosis Int 2002;13(6):501-505.
57. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo- controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 2000;85(5):1895-9000.
58. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnson CC Jr. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998;83(2):396-402.
59. Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blrank MA. The Risedronate Endoscopy Study Group. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and aledronate in postmenopausal women. Gastroenterology 2000;119:631-638.
60. Marshall JK, Rainsford KD, James C, Hunt RH. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 2000;14:1451-1457.
61. Donahue JG, Chan KA, Andrade SE, Beck A, Boles M, Buist M et al. Gastric and duodenal safety of daily alendronate. Arch Intern Med 2002;162:936-942.
62. Lanza F, Sabba B, Schwartz H, et al. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: A placebo-controlled endoscopy study. Am J Gastroenterol 2002;97(1):58-64.
63. Cramer MP, Saks SR. Translating safety, efficacy, and compliance into economic value for controlled release dosage forms. Pharmacoeconomics 1994;5(6):482-504.
64. Branche GC, Batts JM, Dowdy VM, Fields LS, Francis CK. Improving compliance in an inner-city hypertensive patient population. Am J Med 1991;91(1A):37S-41S.
65. Younes H, Farhat G, Fuleihan GH. Efficacy and tolerability of cyclical intravenous pamidronate in patients with low bone mass. J Clin Densitom 2002;5(2):143-149.
66. AmerisourceBergen. IEcho Online Catalog. Cited [17July2002]. Available at URL:https://www.amerisource.com/iechov3/jsp/mainjsp.
67. Liebman M. ed. Awakening the silent osteoporosis market. Cited [2 September 2002]. Available from URL: http://www.cpsnet. com/reprints/2002/04/osteo.pdf.
68. Zhang LIU, Endo N, Yamamoto N, Tanizawa T, Takahashi HE. Effects of single and concurrent intermittent administration of human PTH (1-34) and incadronate on calcellous and cortical bone of femoral neck on ovariectomized rats. Tohoku J Exp Med 1998;186(2):131-141.
69. New data released for ibandronate in postmenopausal women with osteoporosis. Cited [2 Sept 2002]. Available from URL: http://www.rocheusa.com/newsroom/current/2002/pr2002051401.html.
70. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344(19):1434-1441.
71. Burton A. WCO: Strontium ranelate reduces vertebral risk in post-menopausal osteoporosis. Cited [2 Sept 2002]. Available from URL: http://www.pslgroup.com/dg/21555a.htm.
72. Naini BV, Parhami F. IL-1 beta promotes adipogenesis of marrow stromal cells: Further evidence for the role of cytokines in osteoporosis. Cited [2 Sept 2002]. Available from URL: http://research.mednet.ucla.edu/programs/sttp.abstract_public.cfm? abstract_number=203
73. Research reveals advantages of low dose HRT. Highlights in Fertility and Sterility 2001;75(6):1-2. Cited [2 Sept 2002]. Available from URL: http://www.asrm.org/Media/Press/06-01f&s.html.